New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 14, 2013
06:03 EDTBRK.A, RBS, GM, PAA, FIATY, JPM, FOn the Fly: Periodicals Wrap-Up
WALL STREET JOURNAL: Will this finally be the year that investors dump bonds and return to stocks? Some signs are indicating that maybe, possibly, the tide is beginning to reverse. For the week ended Wednesday, U.S. investors plowed $18B into stock mutual funds and exchange-traded funds, the largest one-week total since June 2008, the Wall Street Journal reports...Auto makers (GM, F, FIATY) have found a quicker path to improved fuel efficiency, reinventing the way traditional gas-powered cars are built. They’re cutting weight by substituting more plastics, aluminum and magnesium, including materials once found only in high-end race cars, the Wall Street Journal reports...REUTERS: The U.S. economy is expected to grow by 2.5% in 2013, improving to 3.5% growth in 2014, said Chicago Fed President Charles Evans. He also forecast the U.S. unemployment rate would be 7.4% this year, easing to about 7% in 2014, Reuters reports...CVC Capital Partners and Royal Bank of Scotland (RBS) sold a combined $290M stake in Hong Kong-listed luggage maker Samsonite International, according to a term sheet, Reuters reports...BLOOMBERG: JPMorgan Chase’s (JPM) board will consider releasing an internal report this week that faults CEO Jamie Dimon’s oversight of a division that lost more than $6.2B on botched trades, sources say, Bloomberg reports...A group of oil and gas pipeline operators led by Plains All American Pipeline LP (PAA) announced plans just in the past three months to spend about $1B on rail depot projects to help move more crude from inland fields to refineries on the coasts.Warren Buffett’s (BRK.A) Burlington Northern Santa Fe LLC, the largest U.S. railroad, spent $400M on terminals in 2012, Bloomberg reports
News For A From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 20, 2015
16:29 EDTAAgilent appoints Rodney Gonsalves as principal accounting officer
Subscribe for More Information
May 18, 2015
19:12 EDTAOn The Fly: After Hours Movers
Subscribe for More Information
17:15 EDTAAgilent down almost 5% after Q2 earnings results, guidance
16:10 EDTAAgilent sees FY15 EPS $1.67- $1.73, consensus $1.69
Subscribe for More Information
16:07 EDTAAgilent sees Q3 EPS 38c-42c, consensus 42c
Sees Q3 revenue $995M-$1.015B, consensus $1B.
16:06 EDTAAgilent reports Q2 EPS 38c, consensus 39c
Subscribe for More Information
15:00 EDTANotable companies reporting after market close
Subscribe for More Information
May 15, 2015
08:08 EDTADarwin Professional presents positive clinical data for ALD403
Alder BioPharmaceuticals announced that six-month follow-up data from its Phase 2 proof-of-concept clinical trial of ALD403, its anti-calcitonin gene-related peptide, or CGRP, antibody for the prevention of frequent episodic migraine, were presented in an oral presentation at the 17th Congress of the International Headache Society in Valencia, Spain. Key Points from Oral Session: Migraine Pathophysiology and CGRP as a Therapeutic Target: A single intravenous dose of ALD403 1000mg demonstrated prolonged efficacy over six months for the preventive treatment of migraine. Over three months, the proportion of patients with a 50%, 75%, and 100% reduction in migraine days for ALD403 and placebo was 61% vs 33%; 33% vs 9%; and 16% vs 0%, respectively. Over six months, the proportion of patients with a 50%, 75%, and 100% reduction in migraine days for ALD403 and placebo was 53% vs 28%; 26% vs 7%; and 11% vs 0%, respectively. ALD403 was well tolerated and there were no differences from placebo in terms of adverse events or laboratory safety data. The migraine prevention proof-of-concept trial was conducted in 163 patients with frequent episodic migraine who had on average nine headache days per month. Patients were given a single intravenous dose of 1000mg of ALD403 or placebo. The primary endpoint was the mean change in migraine headache days from baseline to weeks 5-8, and patients were followed for 24 weeks for additional safety and efficacy analyses.
May 13, 2015
08:08 EDTAAgilent volatility elevated into Q1 and sales outlook
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use